Spots Global Cancer Trial Database for Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

Official Title: A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNDX-5613 in Patients With Colorectal Cancer and Other Solid Tumors

Study ID: NCT05731947

Conditions

Colorectal Cancer

Solid Tumors

Interventions

Revumenib

Chemotherapy

Study Description

Brief Summary: This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of revumenib in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.

Detailed Description: The study will be conducted in two parts. The Phase 1 portion of the study consists of a dose escalation cohort, and a signal-seeking expansion where anti-tumor activity signals will be evaluated. The Phase 2 portion of the study will further confirm the anti-tumor activity signals of revumenib.